Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
Prostate cancer is one of the most common malignant neoplasms in men. Nowadays, the overall mortality rate of this disease continues to increase, including due to the high frequency of primary detection of its widespread and metastatic forms. The effectiveness of hormone therapy of metastatic prosta...
Main Author: | S. V. Popov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5368 |
Similar Items
-
Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
by: Hu L, et al.
Published: (2020-06-01) -
Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
by: Zhuifeng Guo, et al.
Published: (2022-08-01) -
Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer
by: Helen Saxby, et al.
Published: (2022-04-01) -
Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
by: Kenichi Hata, et al.
Published: (2022-11-01) -
Choice of treatment options for metastatic hormone-sensitive prostate cancer
by: R. A. Gafanov, et al.
Published: (2020-12-01)